Bipolar Disorder Therapeutics Market Report 2026

Bipolar Disorder Therapeutics Market Overview

• Bipolar Disorder Therapeutics market size has reached to $7.82 billion in 2025 • Expected to grow to $10.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: A Lifelong Condition That Requires Early Diagnosis And Proper Treatment • Market Trend: The Rise Of Novel Therapies For Bipolar Disorders • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Bipolar Disorder Therapeutics Market?

Bipolar disorder therapeutics refer to medication, including mood stabilizers, antidepressants, antipsychotics, and psychological counseling, to control symptoms. The bipolar disorder therapeutic is used in the treatment and management of bipolar disorders. The main types of drugs in bipolar disorder therapeutics are mood stabilizers, antipsychotic drugs, antidepressant drugs, and other drugs. Mood stabilizers refer to a class of medications used in the management and treatment of bipolar disorders. The different mechanisms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Bipolar Disorder Therapeutics Market Growth Forecast?

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing demand for precision psychiatry solutions, expansion of long-acting injectable therapies, growing integration of digital therapeutics, rising focus on treatment adherence improvement, increasing investment in mental health research. Major trends in the forecast period include increasing development of novel mood stabilizing therapies, rising adoption of atypical antipsychotic medications, growing focus on personalized mental health treatment, expansion of combination drug therapies, enhanced integration of digital mental health support.

Global Bipolar Disorder Therapeutics Market Segmentation

1) By Drug Class: Mood Stabilizers, Antipsychotic Drugs, Antidepressant Drugs, Other Drugs 2) By Mechanism: Selective Serotonin Reuptake Inhibitors, Serotonin-norepinephrine Reuptake Inhibitors, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors, Benzodiazepines, Other Mechanisms 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Mood Stabilizers: Lithium, Anticonvulsants 2) By Antipsychotic Drugs: Atypical Antipsychotics, Typical Antipsychotics 3) By Antidepressant Drugs: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs) 4) By Other Drugs: Benzodiazepines, Adjunctive Therapies

What Is The Driver Of The Bipolar Disorder Therapeutics Market?

The increasing healthcare expenditure is expected to propel the growth of the bipolar disorder therapeutics market going forward. Healthcare infrastructure refers to all costs or outlays for medical care, preventative measures, public health initiatives, rehabilitation, community health activities, and health research. Increasing healthcare expenditure can be attributed to several factors, including an aging population, a rise in chronic diseases, and higher drug costs, all of which significantly contribute to the growing demand for medical services and treatments. As awareness of mental health issues rises, the diagnosis of bipolar disorder increases, leading to a higher demand for therapeutic interventions. For instance, in November 2023, according to the Canadian Institute for Health Information, a Canada-based non-profit organization, total health spending in Canada is anticipated to rise by 2.8% in 2023, following a modest growth of just 1.5% in 2022. Therefore, the increasing healthcare expenditure is driving the growth of the bipolar disorder therapeutics industry.

Key Players In The Global Bipolar Disorder Therapeutics Market

Major companies operating in the bipolar disorder therapeutics market are AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Gedeon Richter PLC, Sumitomo Pharma Co. Ltd., H. Lundbeck A/S, Sanofi S.A., Allergan plc, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, NeuroRx Inc., IntraCellular Therapies Inc., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

Global Bipolar Disorder Therapeutics Market Trends and Insights

Major companies operating in the Bipolar Disorder Therapeutics and related market are developing new treatment for depressive episodes associated with bipolar I or II disorder to meet larger customer bases, more sales, and increase revenue. Among bipolar disorders, bipolar depression is the most prevalent and severe clinical manifestation. If compared to manic/hypomanic episodes, these depressed episodes are linked to a poorer prognosis, longer duration, and more recurrences. For instance, in March 2024, the EDIT-B consortium, a France-based collaborative organization that specializes in developing innovative diagnostic tools and biomarkers, launched myEDIT-B, an innovative blood diagnostic tool designed to provide objective biological data that aids psychiatrists and healthcare professionals in making precise diagnoses. It analyzes RNA editing-based biomarkers and has demonstrated sensitivity and specificity rates above 80%. By facilitating quicker and more accurate diagnoses potentially shortening the wait time to within four weeks myEDIT-B aims to tackle the significant issue of misdiagnosis in mental health, with around 40% of individuals diagnosed with depression possibly having bipolar disorder instead.

What Are Latest Mergers And Acquisitions In The Bipolar Disorder Therapeutics Market?

In June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, acquired the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd for an undisclosed amount. The acquisition enables Neuraxpharm Group to expand its therapeutic product portfolio in Greece and Europe. This agreement aims to extend Neuraxpharm's reach in Greece and harness its deep expertise in the central nervous system (CNS) to offer the right products from its extensive lineup to CNS patients, healthcare professionals, pharmacists, and hospitals across Greece, effectively meeting the healthcare demands of patients in the country. Lyofin Ltd. is a Greece-based pharmaceutical company.

Regional Outlook

North America was the largest region in the bipolar disorder therapeutics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Bipolar Disorder Therapeutics Market?

The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Bipolar Disorder Therapeutics Market Report 2026?

The bipolar disorder therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.